Anya K Bershad1, Katrin H Preller2, Royce Lee3, Sarah Keedy3, Jamie Wren-Jarvis3, Michael P Bremmer3, Harriet de Wit4. 1. Department of Psychiatry, University of California Los Angeles, Los Angeles, California. 2. Pharmaco-Neuroimaging and Cognitive-Emotional Processing, Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital for Psychiatry Zurich, Zurich, Switzerland. 3. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois. 4. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois. Electronic address: hdew@uchicago.edu.
Abstract
BACKGROUND: The practice of "microdosing," or the use of repeated, very low doses of lysergic acid diethylamide (LSD) to improve mood or cognition, has received considerable public attention, but empirical studies are lacking. Controlled studies are needed to investigate both the therapeutic potential and the neurobiological underpinnings of this pharmacologic treatment. METHODS: The present study was designed to examine the effects of a single low dose of LSD (13 μg) versus placebo on resting-state functional connectivity and cerebral blood flow in healthy young adults. Twenty men and women, 18 to 35 years old, participated in 2 functional magnetic resonance imaging scanning sessions in which they receivedplacebo or LSD under double-blind conditions. During each session, the participants completed drug effect and mood questionnaires, and physiological measures were recorded. During expected peak drug effect, they underwent resting-state blood oxygen level-dependent and arterial spin labeling scans. Cerebral blood flow as well as amygdala and thalamic connectivity were analyzed. RESULTS:LSD increased amygdala seed-based connectivity with the right angular gyrus, right middle frontal gyrus, and the cerebellum, and decreased amygdala connectivity with the left and right postcentral gyrus and the superior temporal gyrus. This low dose of LSD had weak and variable effects on mood, but its effects on positive mood were positively correlated with the increase in amygdala-middle frontal gyrus connectivity strength. CONCLUSIONS: These preliminary findings show that a very low dose of LSD, which produces negligible subjective changes, alters brain connectivity in limbic circuits. Additional studies, especially with repeated dosing, will reveal whether these neural changes are related to the drug's purported antidepressant effect.
RCT Entities:
BACKGROUND: The practice of "microdosing," or the use of repeated, very low doses of lysergic acid diethylamide (LSD) to improve mood or cognition, has received considerable public attention, but empirical studies are lacking. Controlled studies are needed to investigate both the therapeutic potential and the neurobiological underpinnings of this pharmacologic treatment. METHODS: The present study was designed to examine the effects of a single low dose of LSD (13 μg) versus placebo on resting-state functional connectivity and cerebral blood flow in healthy young adults. Twenty men and women, 18 to 35 years old, participated in 2 functional magnetic resonance imaging scanning sessions in which they received placebo or LSD under double-blind conditions. During each session, the participants completed drug effect and mood questionnaires, and physiological measures were recorded. During expected peak drug effect, they underwent resting-state blood oxygen level-dependent and arterial spin labeling scans. Cerebral blood flow as well as amygdala and thalamic connectivity were analyzed. RESULTS: LSD increased amygdala seed-based connectivity with the right angular gyrus, right middle frontal gyrus, and the cerebellum, and decreased amygdala connectivity with the left and right postcentral gyrus and the superior temporal gyrus. This low dose of LSD had weak and variable effects on mood, but its effects on positive mood were positively correlated with the increase in amygdala-middle frontal gyrus connectivity strength. CONCLUSIONS: These preliminary findings show that a very low dose of LSD, which produces negligible subjective changes, alters brain connectivity in limbic circuits. Additional studies, especially with repeated dosing, will reveal whether these neural changes are related to the drug's purported antidepressant effect.
Authors: Anya K Bershad; Scott T Schepers; Michael P Bremmer; Royce Lee; Harriet de Wit Journal: Biol Psychiatry Date: 2019-06-03 Impact factor: 13.382
Authors: Chi-Hua Chen; John Suckling; Cinly Ooi; Cynthia H Y Fu; Steve C R Williams; Nicholas D Walsh; Martina T Mitterschiffthaler; Emilio Merlo Pich; Ed Bullmore Journal: Neuropsychopharmacology Date: 2007-11-07 Impact factor: 7.853
Authors: Nynke A Groenewold; Esther M Opmeer; Peter de Jonge; André Aleman; Sergi G Costafreda Journal: Neurosci Biobehav Rev Date: 2012-12-01 Impact factor: 8.989
Authors: David C Alsop; John A Detre; Xavier Golay; Matthias Günther; Jeroen Hendrikse; Luis Hernandez-Garcia; Hanzhang Lu; Bradley J MacIntosh; Laura M Parkes; Marion Smits; Matthias J P van Osch; Danny J J Wang; Eric C Wong; Greg Zaharchuk Journal: Magn Reson Med Date: 2014-04-08 Impact factor: 4.668
Authors: Rainer Kraehenmann; André Schmidt; Karl Friston; Katrin H Preller; Erich Seifritz; Franz X Vollenweider Journal: Neuroimage Clin Date: 2015-08-22 Impact factor: 4.881
Authors: Balázs Szigeti; Laura Kartner; Allan Blemings; Fernando Rosas; Amanda Feilding; David J Nutt; Robin L Carhart-Harris; David Erritzoe Journal: Elife Date: 2021-03-02 Impact factor: 8.140
Authors: Robin J Murphy; Rachael L Sumner; William Evans; David Menkes; Ingo Lambrecht; Rhys Ponton; Frederick Sundram; Nicholas Hoeh; Sanya Ram; Lisa Reynolds; Suresh Muthukumaraswamy Journal: Trials Date: 2021-04-23 Impact factor: 2.279
Authors: John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane Journal: Front Psychiatry Date: 2021-12-17 Impact factor: 4.157
Authors: Friederike Holze; Matthias E Liechti; Nadia R P W Hutten; Natasha L Mason; Patrick C Dolder; Eef L Theunissen; Urs Duthaler; Amanda Feilding; Johannes G Ramaekers; Kim P C Kuypers Journal: Clin Pharmacol Ther Date: 2020-10-18 Impact factor: 6.875
Authors: Friederike Holze; Patrick Vizeli; Laura Ley; Felix Müller; Patrick Dolder; Melanie Stocker; Urs Duthaler; Nimmy Varghese; Anne Eckert; Stefan Borgwardt; Matthias E Liechti Journal: Neuropsychopharmacology Date: 2020-10-15 Impact factor: 7.853